In response to injury, hemodynamic changes, or neurohormonal activation, the heart
undergoes a series of structural and functional changes that have been termed cardiac …

In patients with heart failure, the beneficial effects of drug and device therapies counteract to
some extent ongoing cardiac damage. According to the net balance between these two …

Left ventricular (LV) systolic dysfunction represents a highly treatable cause of heart failure
(HF). A substantial proportion of patients with HF with reduced ejection fraction (EF; HFrEF) …

Dilated cardiomyopathy (DCM) represents one of the most common causes of non-ischemic
heart failure, characterised by ventricular dilation alongside systolic dysfunction. Despite …

Introduction: Dilated cardiomyopathy (DCM) is generally thought as a final common pathway
of several conditions leading to the same clinical phenotype. Multiple imaging modalities …

Sudden cardiac death and arrhythmia-related events in patients with non-ischaemic dilated
cardiomyopathy (NICM) have been significantly reduced over the last couple of decades as …

This open access book presents a comprehensive overview of dilated cardiomyopathy,
providing readers with practical guidelines for its clinical management. The first part of the …

Abstract Aims Lake Louise Criteria (LLC) are time-dependent and some acute myocarditis
(AM) with preserved left ventricular ejection fraction (LVEF) could be missed, due to the …

Abstract Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk
for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk …

Aims In patients with recently diagnosed non‐ischaemic LV systolic dysfunction, left
ventricular reverse remodelling (LVRR) and favourable prognosis has been documented in …